



Used in Lieu of PTO/SB/08A/B
(Based on PTO 04-07 version)

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet

1

of

4

Complete if Known	
Application Number	10/568,819-Conf. #7604
Filing Date	November 3, 2006
First Named Inventor	David S. GARVEY
Art Unit	N/A
Examiner Name	Not Yet Assigned
Attorney Docket Number	0102258.00174US3

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Document Number Number-Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
AA*	US-10,715-P		12-08-1998	Mak	
AB*	US-37,234-E		06-19-2001	Garvey et al.	
AC*	US-38,103-E		04-29-2003	Guay et al.	
AD*	US-4,780,401		10-25-1988	Heusser et al.	
AE*	US-4,845,079		07-04-1989	Luly et al.	
AF*	US-4,885,292		12-05-1989	Ryono et al.	
AG*	US-4,894,437		01-16-1990	TenBrink	
AH*	US-4,980,283		12-25-1990	Huang et al.	
AI*	US-5,036,053-A		07-30-1991	Himmelsbach et al.	
AJ*	US-5,036,054-A		07-30-1991	Kaltenbronn et al.	
AK*	US-5,034,512-A		07-23-1991	Hudspeth et al.	
AL*	US-5,055,466-A		10-08-1991	Weller, III et al.	
AM*	US-5,063,207-A		11-05-1991	Doherty et al.	
AN*	US-5,063,208-A		11-05-1991	Rosenberg et al.	
AO*	US-5,064,965-A		11-12-1991	Ocain et al.	
AP*	US-5,066,643-A		11-19-1991	Abeles et al.	
AQ*	US-5,071,837-A		12-10-1991	Doherty et al.	
AR*	US-5,075,451-A		12-24-1991	Ocain et al.	
AS*	US-5,089,471-A		02-18-1992	Hanson et al.	
AT*	US-5,095,006-A		03-10-1992	Bender et al.	
AU*	US-5,095,119-A		03-10-1992	Ocain et al.	
AV*	US-5,098,924-A		03-24-1992	Poss	
AW*	US-5,106,835-A		04-21-1992	Albright et al.	
AX*	US-5,109,869-A		04-14-1992	Albright et al.	
AY*	US-5,114,937-A		05-19-1992	Hamby et al.	
AZ*	US-5,116,835-A		05-26-1992	Ruger et al.	
AA1*	US-5,138,069-A		08-11-1992	Carini et al.	
AB1*	US-5,217,976		06-08-1993	Ratcliffe et al.	
AC1*	US-5,234,936		08-10-1993	Primeau et al.	
AD1*	US-5,252,165-A		11-16-1993	Govil et al.	
AE1*	US-5,284,872-A		02-08-1994	Sandrock et al.	
AF1*	US-5,344,991-A		09-06-1994	Reitz et al.	
AG1*	US-5,380,738-A		01-10-1995	Norman et al.	
AH1*	US-5,380,758-A		01-10-1995	Stamler et al.	
AI1*	US-5,393,790-A		02-28-1995	Reitz et al.	
AJ1*	US-5,409,944-A		04-25-1995	Black et al.	
AK1*	US-5,428,061-A		06-27-1995	Sandrock et al.	
AL1*	US-5,434,178-A		07-18-1995	Talley et al.	
AM1*	US-5,436,265-A		07-25-1995	Black et al.	
AN1*	US-5,466,823-A		11-14-1995	Talley et al.	
AO1*	US-5,474,995-A		12-12-1995	Ducharme et al.	
AP1*	US-5,510,368-A		04-23-1996	Lau et al.	
AQ1*	US-5,536,752-A		07-16-1996	Ducharme et al.	
AR1*	US-5,550,142		08-27-1996	Ducharme et al.	
AS1*	US-5,552,422		09-03-1996	Gauthier et al.	
AT1*	US-5,604,253		02-18-1997	Lau et al.	

Examiner Signature	Date Considered
--------------------	-----------------

<p>Substitute for form 1449/PTO</p> <p>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</p> <p><i>(Use as many sheets as necessary)</i></p>				Complete If Known	
				Application Number	10/568,819-Conf. #7604
				Filing Date	November 3, 2006
				First Named Inventor	David S. GARVEY
				Art Unit	N/A
Examiner Name	Not Yet Assigned				
Sheet	2	of	4	Attorney Docket Number	0102258.00174US3

AU1*	US-5,639,780	06-17-1997	Lau et al.	
AV1*	US-5,650,447	07-22-1997	Keefer et al.	
AW1*	US-5,661,129	08-26-1997	Feelisch et al.	
AX1*	US-5,703,073-A	12-30-1997	Garvey et al.	
AY1*	US-5,807,847	09-15-1998	Thatcher et al.	
AZ1*	US-5,859,053	01-12-1999	Lesur et al.	
AA2*	US-5,874,437	02-23-1999	Garvey et al.	
AB2*	US-5,883,122	03-16-1999	Thatcher et al.	
AC2*	US-5,910,316	06-08-1999	Keefer et al.	
AD2*	US-5,932,538	08-03-1999	Garvey et al.	
AE2*	US-5,932,598	08-03-1999	Talley et al.	
AF2*	US-5,958,926	09-28-1999	Garvey et al.	
AG2*	US-5,962,500	10-05-1999	Eide et al.	
AH2*	US-5,994,294	11-30-1999	Garvey et al.	
AI2*	US-6,010,715	01-04-2000	Wick et al.	
AJ2*	US-6,057,347	05-02-2000	Garvey et al.	
AK2*	US-6,071,531	06-06-2000	Jona et al.	
AL2*	US-6,133,272	10-17-2000	Garvey et al.	
AM2*	US-6,172,068	01-09-2001	Garvey et al.	
AN2*	US-6,177,428	01-23-2001	Garvey et al.	
AO2*	US-6,197,778	03-06-2001	Garvey et al.	
AP2*	US-6,197,782	03-06-2001	Garvey et al.	
AQ2*	US-6,211,179	04-03-2001	Garvey et al.	
AR2*	US-6,221,881	04-24-2001	Garvey et al.	
AS2*	US-6,232,321	05-15-2001	Garvey et al.	
AT2*	US-6,232,336	05-15-2001	Hrabie et al.	
AU2*	US-6,297,260	10-02-2001	Bandarage et al.	
AV2*	US-6,300,356-B1	10-09-2001	Segal et al.	
AW2*	US-6,316,457	11-13-2001	Garvey et al.	
AX2*	US-6,331,542	12-18-2001	Carr et al.	
AY2*	US-6,633,272	10-14-2003	Kumagawa et al.	
AZ2*	US-5,177,097	01-05-1993	Poss	
AA3*	US-5,250,548	10-05-1993	Winn et al.	
AB3*	US-5,256,695	10-26-1993	Poss	
AC3*	US-5,302,610	04-12-1994	Manning et al.	
AD3*	US-5,326,776	07-05-1994	Winn et al.	
AE3*	US-5,451,597	09-19-1995	Bovy et al.	
AF3*	US-5,565,464	10-15-1996	Salimbeni et al.	
AG3*	US-5,645,839	07-08-1997	Chobanian et al.	
AH3*	US-5,663,186	09-02-1997	Nelson et al.	
AI3*	US-5,846,991	12-08-1998	Tanikawa et al.	
AJ3*	US-6,201,002	03-13-2001	Beere et al.	
AK3*	US-20030144277-A1	07-31-2003	DeLucca	
AL3*	US-2003/0216384-A1	11-20-2003	Stokes	
AM3*	US-20050059687-A1	03-17-2005	Makings et al.	

FOREIGN PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear
		Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)			
Examiner Signature				Date Considered	

Substitute for form 1449/PTO				Complete If Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Application Number	10/568,819-Conf. #7604
<i>(Use as many sheets as necessary)</i>				Filing Date	November 3, 2006
				First Named Inventor	David S. GARVEY
				Art Unit	N/A
				Examiner Name	Not Yet Assigned
Sheet	3	of	4	Attorney Docket Number	0102258.00174US3

BA	EP-1336602	08-20-2003	Scaramuzzino Giovanni	
BB	EP-1393722	03-03-2004	Depadova Anthony S	
BC	WO-06/079610	01-20-2006	Nicox S.A.	
BD	WO-05/011646	07-20-2004	Nicox S.A.	
BE	WO-04/054575	12-17-2003	Novartis AG	
BF	WO-03/000295	01-03-2003	Pfizer Prod Inc et al.	
BG	WO-03/013432	02-20-2003	Garvey et al.	
BH	WO-03/017996-A1	03-06-2003	Martin	
BI	WO-02/11707	02-14-2002	Del Soldato et al.	
BJ	WO-02/30866-A1	04-18-2002	Del Soldato et al.	
BK	WO-02/39987	05-23-2002	Neurosearch As et al.	
BL	WO-02/053185	07-11-2002	Lingnau et al.	
BM	WO-02/053188-A1	07-11-2002	Naggi et al.	
BN	WO-02/062017-A1	08-08-2002	Grunenwald	
BO	WO-01/00563-A1	01-04-2001	Benedini et al.	
BP	WO-01/04082-A1	01-18-2001	Castaldi et al.	
BQ	WO-01/10814-A1	02-15-2001	Benedini et al.	
BR	WO-01/12584	02-22-2001	Del Soldato	
BS	WO-01/45703-A1	06-28-2001	Bandarage et al.	
BT	WO-01/87343	11-22-2001	Scolnick et al.	
BU	WO-00/28988-A1	05-25-2000	Garvey et al.	
BV	WO-00/51988-A1	09-08-2000	Benedini et al.	
BW	WO-00/54756	09-21-2000	Thatcher et al.	
BX	WO-00/61537	10-19-2000	Del Soldato	
BY	WO-00/61541-A3	10-19-2000	Del Soldato	
BZ	WO-00/61549	10-19-2000	Del Soldato	
BA1	WO-00/61604	10-19-2000	Del Soldato	
BB1	WO-00/72838-A1	12-07-2000	Eek et al.	
BC1	WO-99/14174	03-25-1999	Bayer Ag et al.	
BD1	WO-99/67231-A1	12-29-1999	Del Soldato	
BE1	WO-98/09948	03-12-1998	Del Soldato et al.	
BF1	WO-98/19672-A1	05-14-1998	Garvey et al.	
BG1	WO-98/21193-A1	05-22-1998	Del Soldato	
BH1	WO-98/30216	07-16-1998	Merck & Co Inc et al.	
BI1	WO-97/14691-A1	04-24-1997	Belley et al.	
BJ1	WO-97/16435-A1	05-09-1997	Black et al.	
BK1	WO-97/27749-A1	08-07-1997	Garvey et al.	
BL1	WO-97/46521-A1	12-11-1997	Thatcher et al.	
BM1	WO-96/03387-A1	02-08-1996	Weier et al.	
BN1	WO-96/03388-A1	02-08-1996	Khanna et al.	
BO1	WO-96/06840-A1	03-07-1996	Prasit et al.	
BP1	WO-96/21667-A1	07-18-1996	Gauthier et al.	
BQ1	WO-96/31509-A1	10-10-1996	Beswick et al.	
BR1	WO-96/36623-A1	11-21-1996	Black et al.	
BS1	WO-95/00501-A3	01-05-1995	Ducharme et al.	
BT1	WO-95/09831-A1	04-13-1995	Del Soldato	

Examiner Signature		Date Considered
-----------------------	--	--------------------

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Complete if Known	
Sheet	4	of	4	Application Number	10/568,819-Conf. #7604
				Filing Date	November 3, 2006
				First Named Inventor	David S. GARVEY
				Art Unit	N/A
				Examiner Name	Not Yet Assigned
				Attorney Docket Number	0102258.00174US3

	BU1	WO-95/15316-A1	06-08-1995	Talley et al.	
	BV1	WO-95/19952-A1	07-27-1995	Bron et al.	
	BW1	WO-95/26188	10-05-1995	Merck & Co Inc et al.	
	BX1	WO-95/30641-A1	11-16-1995	Del Soldato et al.	
	BY1	WO-94/03387-A1	02-17-1994	Reid	
	BZ1	WO-94/03421	02-17-1994	Byrne et al.	
	BA2	WO-94/03435	02-17-1994	Du Pont	
	BB2	WO-94/04484-A1	03-03-1994	Matji et al.	
	BC2	WO-94/12463-A1	06-09-1994	Arena	
	BD2	WO-94/15723-A1	07-21-1994	Bakula	
	BE2	WO-94/20480-A1	09-15-1994	Black et al.	
	BF2	WO-94/26731-A1	11-24-1994	Gauthier et al.	
	BG2	WO-94/27980-A1	12-08-1994	Norman et al.	
	BH2	WO-93/09806-A1	05-27-1993	Stamler, et al.	
	BI2	WO-92/01667	02-06-1992	Searle & Co	
	BJ2	WO-92/02257	02-20-1992	Searle & Co	
	BK2	WO-92/04335	03-19-1992	Searle & Co	
	BL2	WO-91/01724	02-21-1991	Searle & Co	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. * CITE NO.: Those application(s) which are marked with an single asterisk (*) next to the Cite No. are not supplied (under 37 CFR 1.98(a)(2)(iii)) because that application was filed after June 30, 2003 or is available in the IFW. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS					
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.			T ²
	CA	PCT International Search Report for Application No. PCT/US2004/026910 dated August 29, 2006.			
	CB	Brideau et al., <i>Inflamm Res.</i> , 45: 68-74 (1996)			
	CC	Drug Facts and Comparisons, Inc., St. Louis, MO, 1993			
	CD	Goodman and Gilman, The Pharmacological Basis of Therapeutics (9th Edition), McGraw-Hill, 1995, Pgs. 617-657			
	CE	Goodman and Gilman, The Pharmacological Basis of Therapeutics (9th Edition), McGraw-Hill, 1995, Pgs. 901-915			
	CF	Green and Wuts, <i>Protective Groups in Organic Synthesis</i> , Third Edition, John Wiley & Sons, New York (1999)			
	CG	Ignarro et al., <i>Proc. Natl. Acad. Sci. USA</i> , 84:9265-9269 (1987)			
	CH	Merck Index on CD-ROM, Twelfth Edition, Version 12:1, 1996			
	CI	Oae et al., <i>Org. Prep. Proc. Int.</i> , 15(3):165-198 (1983)			
	CJ	Palmer et al., <i>Nature</i> , 327:524-526 (1987); Ignarro et al., <i>Proc. Natl. Acad. Sci. USA</i> , 84:9265-9269 (1987)			
	CK	The Physician's Desk Reference, Medical Economics Company, Inc., Oradell, N.J., 1995			

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not

Examiner Signature	Date Considered
--------------------	-----------------